Physician profile
Michael Timmel
NPI 1760472096
$4,204.00
in general payments reported to CMS, 2019-2025
33 companies · $54.99 in 2025
The $54.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,392 · 2020: $890 · 2021: $479 · 2022: $38.16 · 2023: $205 · 2024: $146 · 2025: $54.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $787.68 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $465.61 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $356.01 | 2019-2023 | Breztri |
| Abbvie INC. | $260.32 | 2019-2025 | |
| Allergan, INC. | $250.16 | 2019-2020 | |
| Glaxosmithkline, LLC. | $210.06 | 2020-2024 | Menveo, Bexsero, Shingrix |
| Amgen INC. | $209.92 | 2019-2021 | |
| Amarin Pharma, INC. | $184.36 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $165.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.15 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $155.07 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.40 | 2019-2024 | Jardiance, Ofev |
| Pfizer INC. | $131.65 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $75.93 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $71.58 | 2019-2020 | |
| Corcept Therapeutics | $68.46 | 2023 | Korlym |
| Biohaven Pharmaceuticals, INC. | $60.86 | 2021 | |
| Exact Sciences Corporation | $56.43 | 2024 | Cologuard Collection Kit |
| Adlon Therapeutics L.P. | $45.03 | 2021 | |
| Horizon Therapeutics Plc | $42.25 | 2019 | |
| Radius Health, INC. | $30.03 | 2023 | Tymlos |
| Antares Pharma, INC. | $28.81 | 2019 | |
| Sanofi Pasteur INC. | $27.14 | 2019-2020 | |
| Ibsa Pharma INC. | $18.47 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.30 | 2021 | |
| Zyla Life Sciences, INC. | $14.38 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.47 | 2019 | |
| Neos Therapeutics, LP | $13.25 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.74 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.90 | 2019 | |
| Shire North American Group INC | $11.20 | 2019 | |
| Neuronetics, INC. | $9.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Timmel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.